Citations 1
Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Palumbo, Antonio, Chanan‐Khan, Asher , Mateos, María‐Victoria , Qi, Ming , Schecter, Jordan M. , Amin, Himal, Qin, Xiang , Deraedt, William , Ahmadi, Tahamtan , Spencer, Andrew , Sonneveld, Pieter , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Špıčka, Ivan , Hungria, Vânia , Mark, Tomer M , Qi, Ming
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: LBA4-LBA4
